71 related articles for article (PubMed ID: 23848983)
1. TGF-β1 and TNF-α differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma.
Menon DR; Wels C; Bonyadi Rad E; Joshi S; Knausz H; Lade-Keller J; Brandner JM; Schaider H
Pigment Cell Melanoma Res; 2013 Nov; 26(6):912-6. PubMed ID: 23848983
[TBL] [Abstract][Full Text] [Related]
2. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
3. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
[TBL] [Abstract][Full Text] [Related]
4. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
5. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
[TBL] [Abstract][Full Text] [Related]
6. RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors.
Lei FX; Jin L; Liu XY; Lai F; Yan XG; Farrelly M; Guo ST; Zhao XH; Zhang XD
Cell Death Dis; 2018 Jun; 9(6):679. PubMed ID: 29880840
[TBL] [Abstract][Full Text] [Related]
7. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
8. Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
Santini CC; Longden J; Schoof EM; Simpson CD; Jeschke GR; Creixell P; Kim J; Wu X; Turk BE; Rosen N; Poulikakos PI; Linding R
Sci Rep; 2019 Jul; 9(1):10865. PubMed ID: 31350469
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
Carlino MS; Gowrishankar K; Saunders CA; Pupo GM; Snoyman S; Zhang XD; Saw R; Becker TM; Kefford RF; Long GV; Rizos H
Mol Cancer Ther; 2013 Jul; 12(7):1332-42. PubMed ID: 23645591
[TBL] [Abstract][Full Text] [Related]
10. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
11. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
[TBL] [Abstract][Full Text] [Related]
13. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
[TBL] [Abstract][Full Text] [Related]
14. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
Choi J; Landrette SF; Wang T; Evans P; Bacchiocchi A; Bjornson R; Cheng E; Stiegler AL; Gathiaka S; Acevedo O; Boggon TJ; Krauthammer M; Halaban R; Xu T
Pigment Cell Melanoma Res; 2014 Mar; 27(2):253-62. PubMed ID: 24283590
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.
Gray-Schopfer VC; Karasarides M; Hayward R; Marais R
Cancer Res; 2007 Jan; 67(1):122-9. PubMed ID: 17210691
[TBL] [Abstract][Full Text] [Related]
16. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
Caputo E; Miceli R; Motti ML; Taté R; Fratangelo F; Botti G; Mozzillo N; Carriero MV; Cavalcanti E; Palmieri G; Ciliberto G; Pirozzi G; Ascierto PA
J Transl Med; 2014 Jul; 12():216. PubMed ID: 25074438
[TBL] [Abstract][Full Text] [Related]
17. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
18. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
20. Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.
Chan XY; Singh A; Osman N; Piva TJ
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28708099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]